IFNB1 and myeloid sarcoma: Interestingly T cells from MS patients exhibit preferentially a Th1 phenotype [31]–[32], T-bet levels are predictive of IFN-β therapy efficacy in MS patients [33] and T-bet is upregulated in patients with active disease and is downregulated during remission [34].